Journal article
Biased Evaluation in Cancer Drug Trials—How Use of Progression-Free Survival as the Primary End Point Can Mislead
Abstract
This Viewpoint discusses whether the use of progression-free survival as the primary end point in cancer drug trials can result in misleading interpretations of improved overall survival and quality of life.
Authors
Tannock IF; Pond GR; Booth CM
Journal
JAMA Oncology, Vol. 8, No. 5, pp. 679–680
Publisher
American Medical Association (AMA)
Publication Date
May 1, 2022
DOI
10.1001/jamaoncol.2021.8206
ISSN
2374-2437